1Department of Internal medicine, Beaumont Hospital, Dearborn, MI
2Division of Hematology & Oncology, Internal Medicine Department, Beaumont Hospital, Dearborn, MI
American Journal of Medical Case Reports.
2021,
Vol. 9 No. 5, 301-304
DOI: 10.12691/ajmcr-9-5-11
Copyright © 2021 Science and Education PublishingCite this paper: Eman EL-Sawalhy, Najlaa Al-Sudani, Wehbi Hnayni, Shahina Patel. Immunoglobulin D Multiple Myeloma, a More Aggressive Subtype.
American Journal of Medical Case Reports. 2021; 9(5):301-304. doi: 10.12691/ajmcr-9-5-11.
Correspondence to: Eman EL-Sawalhy, Department of Internal medicine, Beaumont Hospital, Dearborn, MI. Email:
Eman.elsawalhy@beaumont.orgAbstract
Immunoglobulin D (IgD) multiple Myeloma (MM) is a very rare subtype of myeloma. It accounts for only 1-2% of all MM patients. It is associated with a rapidly progressive disease and poorer outcomes compared with other MM subtypes. In this case report, we present a case of a sixty-year-old man who presented to our hospital with fatigue, anemia, thrombocytopenia, and acute renal failure. His bone marrow biopsy during admission showed 75.9% of plasma cells with significant light chain burden. He was also found to have severe immunoglobulin deficiency along with a lambda to kappa ratio was <0.01. The diagnosis of IgD MM was established, and he was started on CyBorD (Bortezomib, cyclophosphamide, and dexamethasone). Our patient also required hemodialysis for his kidney failure.
Keywords